Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000011493 | SCV000695731 | pathogenic | Fabry disease | 2016-05-23 | criteria provided, single submitter | clinical testing | Variant summary: The GLA c.1192G>T (p.Glu398X) variant results in a premature termination codon, predicted to cause a truncated (lacking 32 AA residues of the C terminus) or absent GLA protein due to nonsense mediated decay. One in silico tool predicts a damaging outcome for this variant. This variant is absent in 87740 control chromosomes. This variant has been reported to manifest a classical phenotype (Eng_AJHM_1993). Miyamura_JCI_1996 showed that deletions of 12 or more AA residues in the C-terminal region resulted in a complete loss of enzyme activity, indicating the functional importance of the C-terminal region. In addition, OMIM and HGMD classified this variant as pathogenic/DM (disease mutation). Taken together, this variant is classified as pathogenic. |
OMIM | RCV000011493 | SCV000031725 | pathogenic | Fabry disease | 1993-12-01 | no assertion criteria provided | literature only |